title: Protective effect of recombinant murine granulocyte-macrophage colony-stimulating factor against Pseudomonas aeruginosa infection in leukocytopenic mice.
abstract: The effects of recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) against Pseudomonas aeruginosa infection in ICR mice were investigated. Mice were treated with cyclophosphamide (CPA) and were then injected intraperitoneally with rmGM-CSF three times daily, beginning on the day after CPA treatment, for 7 days. The number of peripheral blood leukocytes in both CPA- and rmGM-CSF-treated mice and control CPA-treated mice reached a nadir on day 4, when P. aeruginosa was injected intraperitoneally. The administration of rmGM-CSF significantly increased the proportion of survivors among mice infected with a lethal dose of P. aeruginosa. This effect was further analyzed by monitoring sequential changes in leukocyte count and bacterial growth in various organs. The number of bacteria in the peritoneal cavities, peripheral blood samples, and livers of GM-CSF-treated mice decreased to an undetectable level after a transient increase, and the number was significantly lower than that in control mice. In GM-CSF-treated mice, the neutrophil levels in peripheral blood started to increase 5 days after CPA administration and were consistently higher than those in controls. Furthermore, the neutrophils in GM-CSF-treated mice were more mature morphologically. Thus, the prophylactic effect of rmGM-CSF against P. aeruginosa infection may result from a rapid recovery of myelopoiesis and a partial enhancement of mature neutrophil function.
authors.affiliation: Cancer Center, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Okamura
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: A
authors.initials: A
authors.lastname: Suga
authors.forename: N
authors.initials: N
authors.lastname: Shimono
authors.forename: N
authors.initials: N
authors.lastname: Ohhara
authors.forename: Y
authors.initials: Y
authors.lastname: Hirota
authors.forename: Y
authors.initials: Y
authors.lastname: Sawae
authors.forename: Y
authors.initials: Y
authors.lastname: Niho
mesh_terms: D000818:Animals; D001202:Ascitic Fluid / Q000473:pathology; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use*; D007700:Kinetics; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D051379:Mice; D008813:Mice, Inbred ICR; D011552:Pseudomonas Infections / Q000097:blood / Q000401:mortality / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D003115:Colony-Stimulating Factors; D006133:Growth Substances; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide